# Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

> **NCT03063762** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 69 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **DRUG:** RO6874281

## Key facts

- **NCT ID:** NCT03063762
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-20
- **Primary completion:** 2021-06-14
- **Final completion:** 2021-06-14
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2023-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03063762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03063762, "Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)". Retrieved via MORVS 2026-10-14 from https://api.morvs.ai/clinical/NCT03063762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*